Abstract
Background: Today, many healthcare or dementia organizations, clinicians, and companies emphasize the importance of detection of Alzheimer’s disease in an early phase. This idea has gained considerable momentum due to the development of biomarkers, the recent FDA and EMA approval of three amyloid tracers, and the failure of a number of recent therapeutic trials conducted in the early dementia phase. On the one hand, an early etiological diagnosis can lead to early and more efficacious intervention. On the other hand, it is questioned how early an etiological diagnosis is beneficial to the patient. Here we consider ethical issues related to the process of biomarker testing and the impact on the diagnostic disclosure to patients with mild cognitive impairment due to prodromal Alzheimer’s disease. Methods: A systematic review of the theoretical bioethics literature was performed by using electronic databases. The review was limited to articles published in English between 2003 and 2016. Results: A total of twenty articles were included in our effort to make an analysis of the ethical challenges. One of the biggest challenges was the uncertainty and the predictive value of the biomarker-based diagnosis where patients can be amyloid positive without full certainty whether or when they will develop symptomatic decline due to Alzheimer’s disease. Another challenge was the tension between the right to know versus the wish not to know, the limited efficacy of currently available treatment options, and the opportunities and consequences after receiving such an early diagnosis. Conclusion: Based on the results and the additional comments in the discussion, several unanswered questions emerged. Therefore, careful consideration of all these ethical issues is required before the disclosure of a biomarker-based diagnosis to the patient with mild cognitive impairment due to Alzheimer’s disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antoine, P., and F. Pasquier. 2013. Emotional and psychological implications of early AD diagnosis. The Medical Clinics of North America 97(3): 459–475.
Bamford, C., S. Lamont, M. Eccles, L. Robinson, C. May, and J. Bond. 2004. Disclosing a diagnosis of dementia: A systematic review. International Journal of Geriatric Psychiatry 19(2): 151–169.
Bortolotti, L., and H. Widdows. 2011. The right not to know: The case of psychiatric disorders. Journal of Medical Ethics 37(11): 673–676.
Cahill, S., M. Clark, H. O’Connell, B. Lawlor, R.F. Coen, and C. Walsh. 2008. The attitudes and practices of general practitioners regarding dementia diagnosis in Ireland.” International Journal of Geriatric Psychiatry 23(7): 663–669.
Carr, D.B., and D. O’Neill. 2015. Mobility and safety issues in drivers with dementia. International Psychogeriatrics / IPA 27(10): 1613–22.
Carr, D.B., and B.R. Ott. 2010. The older adult driver with cognitive impairment “It’s a very frustrating life.” Journal of the American Medical Association 303(16): 1632–1641.
Chiu, H.F.K., and H. Brodaty. 2013. Arguments against the biomarker-driven diagnosis of AD. Journal Article. International Psychogeriatrics / IPA 25(2): 177–181.
Cornett, P.F., and J.R. Hall. 2008. Issues in disclosing a diagnosis of dementia. Archives of Clinical Neuropsychology 23(3): 251–256.
Daly, M.P. 1999. Diagnosis and management of Alzheimer disease. The Journal of the American Board of Family Practice 12(5): 375–385.
Davis, D.S. 2014. Alzheimer disease and re-emptive suicide. Journal of Medical Ethics 40(8): 543–549.
Dierickx, K. 1998. The human genome and the right not to know. Exploration of the moral grounds. In The Convention of the Human Rights and Biomedicine of the Council of Europe, edited by H. Nys, 173–184. Antwerpen—Groningen: Intersentia rechtswetenschappen.
Draper, B. 2015. Suicidal behavior and assisted suicide in dementia. International Psychogeriatrics / IPA 27(10): 1601–1611.
Draper, B., C. Peisah, J. Snowdon, and H. Brodaty. 2010. Early dementia diagnosis and the risk of suicide and euthanasia. Alzheimer’s & Dementia 6(1): 75–82.
Dworkin, R. 1986. Autonomy and the demented self. The Milbank Quarterly 64 (S2): 4–16.
Fallowfield, L. 1993. Giving sad and bad news. Lancet 341(8843): 476–78.
Gauthier, S., A. Leuzy, E. Racine, and P. Rosa-Neto. 2013. Diagnosis and management of Alzheimer’s disease: Past, present and future ethical issues. Progress in Neurobiology 110(November): 102–113.
Heal, H.C., and H.J. Husband. 1998. Disclosing a diagnosis of dementia: Is age a factor?” Aging & Mental Health 2(2). Routledge: 144–150.
Hirsh, H.L. 1990. Legal and ethical considerations in dealing with Alzheimer’s disease. Legal Medicine, January, 261–326.
Holstein, M.B. 1998. Ethics and Alzheimer’s disease: Widening the lens. The Journal of Clinical Ethics 9(1): 13–22.
Howe, E. 2013. Clinical implications of the new diagnostic guidelines for dementia. Innovations in Clinical Neuroscience 10(5–6): 32–38.
Husband, H.J. 2000. Diagnostic disclosure in dementia: An opportunity for intervention? International Journal of Geriatric Psychiatry 15(6): 544–547.
Johnson, R., K. Harkins, M. Cary, P. Sankar, and J. Karlawish. 2015. The relative contributions of disease label and disease prognosis to Alzheimer’s stigma: A vignette-based experiment. Social Science & Medicine 143(October): 117–127.
Karlawish, J. 2011. Addressing the ethical, policy, and social challenges of creclinical Alzheimer disease. Neurology 77(15): 1487–1493.
Klein, E.P., and J. Kaye. 2013. Dementia specialists and early adoption of amyloid imaging. Journal of Alzheimer’s Disease 33(2): 445–450.
Le Couteur, D.G., J. Doust, H. Creasey, and C. Brayne. 2013. Political drive to screen for pre-dementia: Not evidence based and ignores the harms of diagnosis. BMJ (Clinical Research Ed.) 347(January): f5125.
Leuzy, A., and S. Gauthier. 2012. Ethical issues in Alzheimer’s disease: An overview. Expert Review of Neurotherapeutics 12(5): 557–567.
Maguire, C.P., M. Kirby, R. Coen, D. Coakley, B.A. Lawlor, and D. O’Neill. 1996. Family members’ attitudes toward telling the patient with Alzheimer’s disease their diagnosis. BMJ (Clinical Research Ed.) 313(7056): 529–530.
Mattsson, N., D. Brax, and H. Zetterberg. 2010. To know or not to know: Ethical issues related to early diagnosis of Alzheimer’s disease. International Journal of Alzheimer’s Disease 2010(January): 1–4.
McDougall, R. 2014. Systematic reviews in bioethics: Types, challenges, and value. Journal of Medicine and Philosophy 39(1): 89–97.
Petersen, R.C., R. Doody, A. Kurz, et al. 2001. Current concepts in mild cognitive impairment. Archives of Neurology 58: 1985–1992.
Porteri, C., and G.B. Frisoni. 2014. Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer’s disease: How and what to tell. A kickstart to an ethical discussion. Frontiers in Aging Neuroscience 6(January): 41.
Porteri, C., S. Galluzzi, C. Geroldi, and G.B. Frisoni. 2010. Diagnosis disclosure of prodromal Alzheimer disease: Ethical analysis of two cases. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques 37(1): 67–75.
Portet, F., P.J. Ousset, P.J. Visser, et al. 2006. Mild cognitive impairment (MCI) in medical practice: A critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer’s Disease. Journal of Neurology, Neurosurgery, and Psychiatry 77(6): 714–718.
Post, S.G. 2000. Key issues in the ethics of dementia care. Neurologic Clinics 18(4): 1011–1022.
Prvulovic, D., and H. Hampel. 2011. Ethical considerations of biomarker use in neurodegenerative diseases – A case study of Alzheimer’s disease. Progress in Neurobiology 95(4): 517–519.
Rice, K., and N. Warner. 1994. Breaking the bad news: What do psychiatrists tell patients with dementia about their illness? International Journal of Geriatric Psychiatry 9(6): 467–471.
Smith, A.P., and B.L. Beattie. 2001. Disclosing a diagnosis of Alzheimer’s disease: Patient and family experiences. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques 28 Suppl 1(March): S67–S71.
Snyder, C.H. 2005. Dementia and driving: Autonomy versus safety. Journal of the American Academy of Nurse Practitioners 17(10): 393–402.
Strech, D., M. Mertz, H. Knüppel, G. Neitzke, and M. Schmidhuber. 2013. The full spectrum of ethical issues in dementia care: Systematic qualitative review. The British Journal of Psychiatry: The Journal of Mental Science 202(June): 400–406.
Turner, S., S. Iliffe, M. Downs, et al. 2004. General practitioners’ knowledge, confidence and attitudes in the diagnosis and management of dementia. Age and Ageing 33(5): 461–467.
van Hout, H., M. Vernooij-Dassen, K. Bakker, M. Blom, and R. Grol. 2000. General practitioners on dementia: Tasks, practices and obstacles. Patient Education and Counseling 39(2–3): 219–225.
Vandenberghe, R., K. Adamczuk, P. Dupont, K. Van Laere, and G. Chételat. 2013a. Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer’s disease. NeuroImage: Clinical 2(January): 497–511.
Vandenberghe, R., K. Adamczuk, and K. Van Laere. 2013b. The interest of amyloid PET imaging in the diagnosis of Alzheimer’s disease. Current Opinion in Neurology 26(6): 646–655.
Viloria Jiménez, M.A., M. Chung Jaén, M. Vigara García, and H. Barahona-Alvarez. 2013. Decision-making in older people with dementia. Reviews in Clinical Gerontology 23(4): 307–316.
Visser, P.J., H. Wolf, G. Frisoni, and H.J. Gertz. 2012. Disclosure of Alzheimer’s disease biomarker status in subjects with mild cognitive impairment. Biomarkers in Medicine 6(4): 365–368.
Werner, P., and A.D. Korczyn. 2008. Mild cognitive impairment: Conceptual, assessment, ethical, and social issues. Clinical Interventions in Aging 3(3): 413–420.
Wilson, J. 2005. To know or not to know? Genetic ignorance, autonomy and paternalism. Bioethics 19(5–6): 492–504.
Witte, M., N. Foster, A. Fleisher, et al. 2015. Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. July.
Wright, C., A. Hall, F. Matthews, and C. Brayne. 2009. Biomarkers, dementia, and public health. Annals of the New York Academy of Sciences 1180(October): 11–19.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
ESM 1
(DOCX 26 kb)
Rights and permissions
About this article
Cite this article
Vanderschaeghe, G., Dierickx, K. & Vandenberghe, R. Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer’s Disease. Bioethical Inquiry 15, 219–230 (2018). https://doi.org/10.1007/s11673-018-9844-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11673-018-9844-y